Sasaki Takashi, Kanata Ryo, Yamada Ikuhiro, Matsuyama Masato, Ozaka Masato, Sasahira Naoki
Department of Gastroenterology, Cancer Institute Hospital of Japanese Foundation of Cancer Research, Tokyo, Japan
Department of Gastroenterology, Cancer Institute Hospital of Japanese Foundation of Cancer Research, Tokyo, Japan.
In Vivo. 2019 Jan-Feb;33(1):271-276. doi: 10.21873/invivo.11471.
BACKGROUND/AIM: FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin) and gemcitabine plus nab-paclitaxel therapy have recently been introduced for the treatment of metastatic pancreatic cancer. Herein, overall treatment outcomes of metastatic pancreatic cancer after introduction of FOLFIRINOX and gemcitabine plus nab-paclitaxel therapy were evaluated, in daily practice.
Metastatic pancreatic cancer patients (n=321) who started systemic chemotherapy between January 2011 and December 2016 were included and were divided into two groups: group A (2011-2013) and group B (2014-2016). Treatment outcomes were evaluated retrospectively.
Patient characteristics were similar between the two groups except for the rates of distant lymph node metastasis and peritoneal metastasis. The preferred regimens in groups A and B were gemcitabine monotherapy and gemcitabine plus nab-paclitaxel therapy, respectively. The response rates, median progression-free survival, and median overall survival of groups A and B were 7.8% and 28.4% (p<0.01), 3.1 months and 5.4 months (p<0.01), and 6.7 months and 10.2 months (p<0.01), respectively.
Overall treatment outcomes for metastatic pancreatic cancer were significantly improved after introduction of FOLFIRINOX and gemcitabine plus nab-paclitaxel combination therapy in daily practice.
背景/目的：FOLFIRINOX（5-氟尿嘧啶、亚叶酸钙、伊立替康、奥沙利铂）和吉西他滨联合纳米白蛋白结合型紫杉醇疗法最近已被用于转移性胰腺癌的治疗。在此，对日常临床中引入FOLFIRINOX和吉西他滨联合纳米白蛋白结合型紫杉醇疗法后转移性胰腺癌的总体治疗结果进行了评估。
纳入2011年1月至2016年12月期间开始全身化疗的转移性胰腺癌患者（n = 321），并将其分为两组：A组（2011 - 2013年）和B组（2014 - 2016年）。对治疗结果进行回顾性评估。
除远处淋巴结转移率和腹膜转移率外，两组患者的特征相似。A组和B组中最常用的治疗方案分别是吉西他滨单药治疗和吉西他滨联合纳米白蛋白结合型紫杉醇疗法。A组和B组的缓解率、中位无进展生存期和中位总生存期分别为7.8%和28.4%（p<0.01）、3.1个月和5.4个月（p<0.01）以及6.7个月和10.2个月（p<0.01）。
在日常临床中引入FOLFIRINOX和吉西他滨联合纳米白蛋白结合型紫杉醇联合疗法后，转移性胰腺癌的总体治疗结果有显著改善。
